American Diabetes Association

77TH SCIENTIFIC SESSIONS

SAN DIEGO, CA • JUNE 9 - 13, 2017

EXPERIENCE NEW HORIZONS IN DIABETES

ADVANCE PROGRAM

scientificsessions.diabetes.org
ABOUT THE MEETING
The American Diabetes Association’s Scientific Sessions offers researchers and health care professionals from around the world the unique opportunity to share ideas and learn about the significant advances in diabetes research, treatment, and care.

Over the course of five days, participants will receive exclusive access to more than 2,500 original research presentations, take part in provocative and engaging exchanges with leading diabetes experts, expand their professional networks, and so much more.

The program is organized into eight distinct theme areas, allowing you to focus on your specialty or expand your knowledge in other areas.

Theme Areas:
- Acute and Chronic Complications
- Behavioral Medicine, Clinical Nutrition, Education, and Exercise
- Clinical Diabetes/Therapeutics
- Epidemiology/Genetics
- Immunology/Transplantation
- Insulin Action/Molecular Metabolism
- Integrated Physiology/Obesity
- Islet Biology/Insulin Secretion

Don’t miss this opportunity to join your colleagues at the world’s largest meeting focused on diabetes—the American Diabetes Association’s 77th Scientific Sessions!

LOCATION AND DATES
The meeting will take place at the San Diego Convention Center
111 West Harbor Drive
San Diego, CA 92101.

The program will begin on Friday, June 9 at 11:30 a.m. with our Mini-Symposia Sessions and conclude on Tuesday, June 13 at 11:45 a.m. after the ADA Presidents Oral Session.

TARGET AUDIENCE
Physicians, scientists, researchers, nurses, nurse practitioners, dietitians, podiatric physicians, pharmacists, psychologists, and other health care professionals involved in diabetes research or the delivery of diabetes care and services will benefit from the comprehensive programming of the Scientific Sessions.

LEARNING OBJECTIVES
The Scientific Sessions offers comprehensive educational programming covering the latest in the field of diabetes.

At the conclusion of this activity attendees will be able to:
- Identify the 2017 ADA Standards of Care for classifying, diagnosing, preventing, and treating prediabetes and diabetes.
- Assess non-pharmacologic treatment options for individualizing treatment protocols for the management of hyperglycemia and hypoglycemia.
- Apply clinical decision making tools to the assessment and treatment of the complications related to diabetes.
- Develop a more aggressive, effective, physiological, psychological, and behavioral treatment plan for patients with diabetes.
- Cite the research into current, emerging, and novel therapies for type 1 and type 2 diabetes.
- Discuss proven education strategies for increasing the impact of diabetes education with individual patients.
- Interpret the latest findings in the areas of epidemiology, genetics, immunology, transplantation, and islet biology as they relate to diabetes.

IMPORTANT DATES TO REMEMBER

<table>
<thead>
<tr>
<th>Important Date</th>
<th>Deadline</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abstract Submission Deadline</td>
<td>March 13</td>
</tr>
<tr>
<td>Registration and Housing Deadlines</td>
<td></td>
</tr>
<tr>
<td>Last day to register at the Advance rate</td>
<td>April 27</td>
</tr>
<tr>
<td>Last day to cancel meeting registration and receive a partial refund (50% of registration fee)</td>
<td>April 27</td>
</tr>
<tr>
<td>Last day to reserve hotel rooms</td>
<td>May 12</td>
</tr>
<tr>
<td>Last day to register online</td>
<td>June 1</td>
</tr>
<tr>
<td>Cancel hotel reservations to avoid penalty</td>
<td>72 hours prior to arrival</td>
</tr>
</tbody>
</table>

Visit scientificsessions.diabetes.org to register.
**PROGRAM INFORMATION**

**Special Addresses and Award Lectures**
- President, Health Care & Education Address
  Brenda Montgomery, RN, MSHS, CDE
- President, Medicine & Science Address
  Alvin C. Powers, MD
- Banting Medal for Scientific Achievement
  Domenico Accili, MD
- Outstanding Scientific Achievement Award Lecture
  Gregory R. Steinberg, PhD
- Outstanding Educator in Diabetes Award Lecture
  Davida F. Kruger, MSN, APRN-BC, BC-ADM
- Kelly West Award for Outstanding Achievement In Epidemiology Lecture
  Dana Dabelea, MD, PhD
- Richard R. Rubin Award Lecture
  Michael A. Harris, PhD
- Roger Pecoraro Award Lecture
  Dane K. Wukich, MD
- Norbert Freinkel Award Lecture
  Gernot Desoye, PhD
- Edwin Bierman Award Lecture
  Mark E. Cooper AO, MBBS, PhD, FRACP

**Mini-Symposia**
These interactive sessions will feature 1-2 speakers presenting on a topic for 20 minutes with the remainder of time devoted to questions and discussion with the audience. Mini-Symposia Sessions will be held on Friday from 11:30 a.m. to 12:30 p.m. and 12:45 p.m. to 1:45 p.m.

**Oral Presentations**
Abstracts selected for oral presentation are considered to be the best of the thousands of abstracts submitted to the Scientific Sessions. Choose from over 380 original presentations highlighting the latest research and investigative methods not found at any other meeting.

**Poster Presentations**
Explore over 2,000 original posters displayed in the Poster Hall on Saturday, Sunday, and Monday. Poster presenters will be at their poster boards for one hour on an assigned day to discuss their research.

**ADA Presidents Oral Session**
Don’t leave the meeting until after you hear the best, cutting-edge research the Scientific Sessions has to offer during the ADA Presidents Oral Session. Featured abstracts will highlight the most recent and innovative advances in both basic and clinical science.

**Moderated Poster Discussions**
Listen in as moderators share their perspectives and highlight novel or recent advancements in question and answer discussions with poster presenters.

Due to the overwhelming popularity of the Moderated Poster Discussions, select discussions will be presented in our ePoster Theaters. The ePoster Theaters are designed to accommodate larger crowds, making for a much more comfortable and enjoyable learning experience.

**Interactive Online Posters**
Unable to meet with a poster presenter? Don’t worry—each poster presented at the Scientific Sessions will have a corresponding barcode on its board. Scan the barcode with your smartphone, tablet, or handheld device to access an electronic version of the poster, corresponding abstract, and audio commentary (if provided). Computer stations will also be located within the Poster Hall for electronic poster viewing.

**Scientific Sessions App**
Access the meeting on-the-go. Download the Scientific Sessions app to access meeting information on your smartphone, tablet, or handheld device. Features include a customizable calendar and itinerary builder, exhibitor listing with interactive booth map, social media interaction, and special meeting alerts.

Visit scientifcsessions.diabetes.org in early May for more details.
Professional Interest Groups
Share your views during hot-topic sessions hosted by the Professional Interest Groups on the latest in research and care specific to your specialty. Interactive lunchtime sessions in the following theme areas will be offered:

- Behavioral Medicine and Psychology
- Clinical Endocrinology, Health Care Delivery, and Public Health
- Complications
- Diabetes in Youth
- Education
- Epidemiology and Statistics
- Exercise
- Foot Care
- Immunology, Immunogenetics, and Transplantation
- Nutritional Science and Metabolism
- Pregnancy and Reproductive Health

After the meeting, Interest Groups contribute to the Association in a variety of valuable ways throughout the year, with members serving on policy-making committees, writing technical reviews, writing position statements, and acting as liaisons with peer organizations. Visit professional.diabetes.org/interestgroups for the latest resources and information.

Exhibit Hall
The Exhibit Hall is a vital part of the Scientific Sessions educational experience. This unparalleled venue provides demonstrations of products and services that will enhance your understanding of the latest advancements in pharmaceuticals, devices, imaging, and services important to high-quality patient care. The Exhibit Hall will be open on Saturday, Sunday, and Monday.

Product Theaters
Industry experts will provide insight into diabetes services and products and demonstrate innovative equipment and technologies. Product Theaters will be conveniently scheduled in the Exhibit Hall on Saturday, Sunday, and Monday.

Corporate Symposia
Corporate Symposia are satellite programs that are planned and conducted by the corporate community in conjunction with the Scientific Sessions. These programs provide attendees with additional education and information opportunities.

Pre-registered attendees will receive an e-mail on or about April 3, which will include instructions on registering for the Corporate Symposia. Attendees who register after April 3 will be able to select the Corporate Symposia when registering.

Visit scientificsessions.diabetes.org in early April for the most up-to-date schedule.

SPECIAL EVENTS
Networking Reception
Join us Friday evening from 6:30 p.m. to 8:30 p.m. out on the terrace of the convention center for a networking reception. Catch up with your colleagues from around the world, and enjoy complimentary light hors d’oeuvres and beverages while renewing connections or making new ones.

5K@ADA Fun Run/Walk
The 5K@ADA Fun Run/Walk, supported by Novo Nordisk, will be held on Sunday morning at 6:30 a.m. Race in style by sporting a 5K@ADA running shirt available for $20 when you register for the meeting. A limited number of shirts will be available for purchase onsite for $25. Sign up for the Fun Run/Walk by visiting www.ada5K.com. The event is free to all registered attendees.

Scientific Sessions Walking Challenge

The first 1,200 attendees to complete the registration form and pick up a tracker will compete in a meeting-long competition to see who takes the most steps! You can register at the Walking Challenge booth during the meeting which will be located in the Sails Pavilion of the convention center.

The challenge will begin on Friday, June 9 at 12:00 p.m. and end on Monday, June 12 at 11:59 p.m. You will need to download an app onto your iOS or Android device.

We challenge all attendees, and those participating in the challenge, to take 77,000 steps over the days of the meeting to commemorate our 77 years of service to those affected by diabetes.

Show Your True Colors—Support the American Diabetes Association by Wearing Red
Wear red on Sunday to show your support of the Association and our mission to prevent and cure diabetes and to improve the lives of all people affected by diabetes. Together, we can achieve a world free of diabetes and all its burdens.
REGISTRATION CATEGORIES

Member
Professional I and II Members. Have your Professional Member ID number available to register as a member. Professional Members who purchase a full meeting registration will receive online access to the Scientific Sessions webcasts free of charge—a $99 value!

Non-Member
For those who are not ADA Professional I or II Members. Become a member when you register for the full meeting registration and save up to $320 off the Non-Member rate. You’ll also receive complimentary online access to the Scientific Sessions webcasts—a $99 value!

One-Day
Provides admittance to all sessions, including the Exhibit Hall and the Poster Hall (if open), for the selected day. You are allowed to register for only 1 One-Day Registration.

Student/Resident/Fellow
Available to those currently enrolled in one of these programs. Proof of status in a program must be submitted in order to register.

Please note:
Children under the age of 18, even if paid registrants, will not be admitted to session rooms, the Exhibit Hall, or the Poster Hall. Exceptions can be made for nursing mothers, but for safety reasons, strollers cannot be allowed in session rooms, the Exhibit Hall and the Poster Hall. Children should be kept quiet as to not interrupt the sessions.

REGISTRATION INFORMATION

Register Online
Go to scientificsessions.diabetes.org and click on the Registration Information tab.

Online registration is fast, easy, and secure. You will receive your confirmation letter and periodic updates via e-mail. If you are unable to register online, a downloadable registration form is available on the Scientific Sessions website.

Attendees should bring their confirmation letter with them onsite to receive their meeting materials. The barcode included on your confirmation letter will greatly speed you through registration. A picture ID will be required to pick up your registration materials.

Questions?
Contact the ADA Registration and Housing Customer Care Center Monday through Friday, 9:00 a.m. to 9:00 p.m. (Eastern Time) at 866-290-9910 (Toll Free U.S. & Canada) or +415-268-2086 (International). Or, visit the ADA Support Center at ada.cmrushelp.com.

Media Registration
The Association provides complimentary access to the Scientific Sessions to credentialed members of the media, including print, broadcast, and online media for the express purpose of gathering news and information to produce original press coverage of the 77th Scientific Sessions. Media representatives welcome to attend include reporters, writers, photographers, and videographers.

News organizations seeking media credentials must be represented by editorial staff and submit the appropriate credentials. To request a complimentary registration as a journalist representing an accredited news organization, please visit scientificsessions.diabetes.org and click on the Media tab to review/approve the Guidelines for Press/Media Representatives, and submit your credentials to press@diabetes.org.

REGISTRATION RATES

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Member*</td>
<td>$545</td>
<td>$595</td>
</tr>
<tr>
<td>Non-Member</td>
<td>$865</td>
<td>$915</td>
</tr>
<tr>
<td>Student/Resident/Fellow</td>
<td>$290</td>
<td>$310</td>
</tr>
<tr>
<td>One-Day Registration — Member*</td>
<td>$310</td>
<td>$320</td>
</tr>
<tr>
<td>One-Day Registration — Non-Member</td>
<td>$400</td>
<td>$410</td>
</tr>
</tbody>
</table>

*In order to qualify for the Member rate your Professional I or II Membership must be active through June 30, 2017 at the time of registration.
HOTEL INFORMATION

Book Online
Go to scientificsessions.diabetes.org and click on the Hotel Information tab.

Reserving your room online allows you to see hotel availability in real time and allows us to send confirmation letters instantly. It also gives us a fast and easy way to contact you via e-mail with any changes or updates.

Hotel Reservations
Support the ADA by booking your hotel room within ADA’s housing block through ADA’s official Housing Company, CMR.

Hotel reservations can be made until May 12 based on availability. A listing of ADA meeting hotels, with rates and a locator map, is available at scientificsessions.diabetes.org. Reservations are available on a first-come, first-served basis. Reserve your room early for the best selection. All hotels require a credit card guarantee. If you are unable to reserve online, a downloadable housing form is available on the Scientific Sessions website.

ADA Shuttle Bus Transportation
Attendees who reserve their room within the Scientific Sessions housing block will receive a shuttle pass, enabling them to ride the ADA shuttle system at no additional cost.

Attendees who reserve their rooms through other means will not receive a shuttle pass. Shuttle passes will be available for purchase in advance through the online registration site and onsite at the meeting at a cost of $75 per person. The pass is valid throughout the duration of the meeting.

International Group Organizers
If you are organizing an international group (five or more rooms) to attend the Scientific Sessions, you may reserve your hotel rooms through our official housing company’s International Group Division, CMR’s Global Group Services website at ada-cmrglobalgroupservices.com, or contact them via e-mail at ada@cmrglobalgroupservices.com for an all-inclusive group housing package. For any questions regarding group registration, visit the ADA Support Center at ada.cmrushelp.com.

Hotel Cancellations and Changes
All requests for cancellations or changes can be made by going online or by contacting ADA’s official housing company. Changes received after May 12 will be subject to hotel availability. Reservations must be cancelled at least 72 hours prior to arrival to avoid penalty charges.

Questions?
Contact the ADA Registration and Housing Customer Care Center Monday through Friday, 9:00 a.m. to 9:00 p.m. (Eastern Time) at 866-290-9910 (Toll Free U.S. & Canada) or +415-268-2086 (International). Or, visit the ADA Support Center at ada.cmrushelp.com.

TRAVEL INFORMATION

Special Travel Discounts
Traveling to the Scientific Sessions by plane or car? Check out the special discounts we have for you! Visit scientificsessions.diabetes.org and click on the Travel and Transportation Information tab for more information.

Visa Requirements
Attendees from outside the U.S. may need to apply for a visa at the American Embassy, consulate, or other visa issuing office in their country of origin. Please begin your visa application process as soon as possible, as it can take several months to receive approval.

If a letter of invitation is needed for your visa application, go to scientificsessions.diabetes.org and click on the Travel and Transportation Information tab to download the letter.

CITY INFORMATION

From the moment you arrive, you’ll understand why San Diego is consistently named a top meeting destination. In addition to year-round sunshine and near-perfect weather, San Diego is soaked in culture, 70+ miles of sparkling coastline, friendly locals, a vibrant downtown, and an endless assortment of unique neighborhoods to explore.

So come early or stay late and discover your favorite way to enjoy San Diego. Whether you want to learn how to surf in La Jolla, taste the local flavors at a five-star restaurant in the Gaslamp Quarter, stroll the peaceful beaches of Coronado, explore the museums of Balboa Park, or take a cruise on the bay, San Diego has something for everyone.

For more information visit http://meetmeinsandiego.com/ada2017.
ACCREDITATION STATEMENTS

Physicians
The American Diabetes Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The American Diabetes Association designates this live activity for a maximum of 35 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Family Physicians
An application for CME credit will be filed with the American Academy of Family Physicians.

Doctors of Osteopathy
Category 2 Credit will be awarded for formal educational programs that are ACCME-accredited or AAFP approved.

Physician Assistants
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME for a recognized state medical society. Physician Assistants may receive a maximum of 35 hours of Category 1 Credit™ for completing this program.

Podiatric Physicians
An application for joint providership will be filed with the American Podiatric Medical Association.

International Physicians
The American Medical Association has determined that physicians not licensed in the U.S. who participate in this CME activity are eligible for AMA PRA Category 1 credit(s)™.

European Union of Medical Specialists
The European Accreditation Council for Continuing Medical Education (EACCME) and the American Medical Association (AMA) signed an agreement of mutual recognition of CME credits between Europe and the USA whereby: 1) European physicians attending an event in the USA had their credits recognized in Europe and 2) American physicians attending an event in Europe had their credits recognized in the USA.

The American Diabetes Association designates this educational activity for a maximum of 35 AMA PRA Category 1 Credit(s)™ for the American Diabetes Association's 77th Scientific Sessions. Each medical specialist should claim only those credits that he/she actually spent in the educational activity. These credits can be converted by the EACCME into European CME credits and/or into National credits by the European National Authorities.

Nurses
The American Diabetes Association is accredited as a provider of continuing education by the American Nurses Credentialing Center’s COA.

California Board of Registered Nursing
The American Diabetes Association is a provider approved by the California Board of Registered Nursing. Provider No. CEP-12196. This activity is approved for 35 contact hours.

Dietitians
The American Diabetes Association is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Diabetic Registration (CDR). Registered dietitians will receive 35 continuing professional education units (CPEUs) for completion of this program/material. Activity Number: 131554.

Pharmacists
The American Diabetes Association is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. ACPE Provider number 0239. The American Diabetes Association designates these sessions as Knowledge-based per ACPE guidelines. To view the UANs and learning objectives for each educational category, visit scientificsessions.diabetes.org and click on the Continuing Education tab.

Psychologists
The American Diabetes Association is approved by the American Psychological Association to sponsor continuing education for psychologists. The American Diabetes Association maintains responsibility for the program and its content. This activity offers a maximum of 35 hours of continuing education credit. Each psychologist must attend in their entirety those sessions designated as offered for psychology credit and claim only those hours spent in the educational activity.

Certified Diabetes Educators
To satisfy the requirement for renewal of certification by continuing education for the National Certification Board for Diabetes Educators (NCBDE), continuing education activities must be diabetes related and approved by a provider on the NCBDE List of Approved Providers (ncbde.org). NCBDE does not approve continuing education. The American Diabetes Association is on the NCBDE List of Approved Providers.

Successful Completion Statement
Certificates of Completion/Attendance are provided to registered attendees based upon completion of the online evaluation. The online evaluation will be available at scientificsessions.diabetes.org from June 9 to July 14, 2017. For questions regarding continuing education, please e-mail professionaleducation@diabetes.org.
## DAY-AT-A-GLANCE SCHEDULE
### FRIDAY, JUNE 9

<table>
<thead>
<tr>
<th>Time</th>
<th>Acute and Chronic Complications</th>
<th>Behavioral Medicine, Clinical Nutrition, Education, and Exercise</th>
<th>Clinical Diabetes/Therapeutics</th>
<th>Epidemiology/Genetics</th>
<th>Immunology/Transplantation</th>
<th>Insulin Action/Molecular Metabolism</th>
<th>Integrated Physiology/Obesity</th>
<th>Islet Biology/Insulin Secretion</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:30 a.m.—12:30 p.m.</td>
<td>Mini-Symposium Clinical Innovation in Vision</td>
<td>Mini-Symposium Exercise for Type 1 Diabetes</td>
<td>Mini-Symposium Provocative Therapies and Clinical Technologies</td>
<td>Mini-Symposium A Researcher’s Guide to Exploring Diabetes Genetic Data in the Type 2 Diabetes Knowledge Portal</td>
<td>Mini-Symposium The Future Face of Diabetes Care—Beta-Cell Replacement vs. Technology</td>
<td>Mini-Symposium The Light and Dark Sides of Circadian Metabolic Regulation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:45 p.m.—1:45 p.m.</td>
<td>Mini-Symposium Translational Science and Diabetic Foot Ulceration (DFU)</td>
<td>Mini-Symposium International Guidelines Regarding Nutrition for Preschoolers with Type 1 Diabetes</td>
<td>Mini-Symposium New Therapies for Diabetes in Youth—What the Future May Bring</td>
<td>Mini-Symposium The History of the ADA Guidelines—Their Influence on the Study of and Clinical Practice in Complications in Type 1 and Type 2 Diabetes</td>
<td>Mini-Symposium Biomarkers of Type 1 Diabetes</td>
<td>Mini-Symposium Human Islet Research Network—NIH-Funded Interactive Research Network</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Acute and Chronic Complications</td>
<td>Behavioral Medicine, Clinical Nutrition, Education, and Exercise</td>
<td>Clinical Diabetes/Therapeutics</td>
<td>Epidemiology/Genetics</td>
<td>Immunology/Transplantation</td>
<td>Insulin Action/Molecular Metabolism</td>
<td>Integrated Physiology/Obesity</td>
<td>Islet Biology/Insulin Secretion</td>
</tr>
<tr>
<td>-----------</td>
<td>---------------------------------</td>
<td>---------------------------------------------------------------</td>
<td>--------------------------------</td>
<td>------------------------</td>
<td>---------------------------</td>
<td>----------------------------------</td>
<td>-------------------------------</td>
<td>-------------------------------</td>
</tr>
</tbody>
</table>
| 2:00 p.m.—4:00 p.m. | **Symposium**
Update on Cardiovascular Outcomes Trials (CVOTs) | **Symposium**
If You Build It, They Will Come—But Will They Stay?
Recruitment and Retention in Diabetes Trials | **Symposia**
Hypoglycemia Prediction Models for Risk Stratification—Prediction to Prevention | **Symposium**
mHealth—Friend or Bystander in Diabetes Management? | **Symposium**
Primer on Transplantation for the Clinician | **Symposium**
Big Data and Generating Novel Hypotheses | | **Symposium**
Chemical Modulation of Beta-Cell Function |
| 4:15 p.m.—6:15 p.m. | **Symposium**
Urologic Complications and Sexual Dysfunction in Diabetes | **Symposium**
Dietary Guidelines for Treatment of Diabetes around the Globe—What Are the Controversies, and What Do Differences in Guidelines Tell Us? | **Symposia**
(4:15 p.m.—5:15 p.m.)
A Heavy Heart—Metals, Diabetes, and Cardiovascular Disease Outcomes SGLT2 Inhibitors—Still More to Explore | | **Symposium**
Can “Omic” and Genome-Wide Association Studies (GWAS) Reveal Therapeutic Links between Type 1 and Type 2 Diabetes? | **Symposium**
Oral Presentations | **Symposium**
Oral Presentations | **Symposium**
Oral Presentations |
| 6:30 p.m.—8:30 p.m. | | | | | | | | | **Networking Reception** |
**DAY-AT-A-GLANCE SCHEDULE**

**SATURDAY, JUNE 10**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Description</th>
</tr>
</thead>
</table>
| 8:00 a.m.—10:00 a.m. | Symposium Thirty-Year Anniversary of the Foot Care Interest Group—The Diabetic Foot; Then and Now  <br> Oral Presentations  
Symposium ADA Education Recognition Program Symposium—Introduction to the 2017 National Standards for Diabetes Self-Management Education and Support  <br> Oral Presentations  
Symposium ADA Diabetes Care Symposium—Diabetes Care and Research through the Ages  <br> Oral Presentations  
Symposium Vivian Fonseca Scholar Award Presentation  <br> Oral Presentations |
| 10:15 a.m.—11:15 a.m. | President, Health Care & Education Address and Outstanding Educator in Diabetes Award Lecture  
Professional Interest Group Session Hyperbaric Oxygen Therapy for Diabetic Foot Ulcers (DFUs)—Fact or Fiction?  
Professional Interest Group Sessions Eating Behaviors in Type 1 Diabetes  
The New Physical Activity/Exercise Guidelines for Diabetes  |
| 11:30 a.m.—12:30 p.m. | General Poster Session  
Moderated Poster Discussions  |
<table>
<thead>
<tr>
<th>Time</th>
<th>Section</th>
<th>Topic</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:45 p.m. — 3:45 p.m.</td>
<td>Symposium Diabetes, Drugs, and Heart Failure</td>
<td>Symposium: The New Psychosocial Position Statement from the ADA — Implications for Practice (With Richard R. Rubin Award Lecture)</td>
<td>Reducing Hospital Readmissions — Effective Transitions Matter</td>
</tr>
<tr>
<td>4:00 p.m. — 6:00 p.m.</td>
<td>Symposium The Atherogenic Dyslipidemia Complex — New Biomarkers and Therapies Beyond LDL</td>
<td>Symposium: Population Health, Affordable Care Act (ACA), and New Approaches for Dissemination/Implementation of the Diabetes Prevention Program (DPP)</td>
<td>Exercise-Regulated Molecular Transducers of Insulin Resistance</td>
</tr>
<tr>
<td></td>
<td>Symposium Overtreatment in Diabetes Management</td>
<td>Symposium: Genome Editing in Islet Biology and Disease</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Symposium Current Status of Complications in Youth with Type 1 Diabetes</td>
<td>Symposium: Insulin Action and Cellular Metabolism</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Into the Endocrine Bowels of Diabetes</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Dealing with the Rising Costs of Insulin — An Active Dialogue</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Symposium: The Good and the Bad of Glucagon Physiology and Therapeutics</td>
<td>ADA Pathway to Stop Diabetes Symposium</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Oral Presentations</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Additional Information:

- Symposium: The New Psychosocial Position Statement from the ADA — Implications for Practice (With Richard R. Rubin Award Lecture)
- Symposium: Genome Editing in Islet Biology and Disease
- Symposium: Insulin Action and Cellular Metabolism
- Symposium: The Good and the Bad of Glucagon Physiology and Therapeutics
- ADA Pathway to Stop Diabetes Symposium
- Oral Presentations
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 8:00 a.m.—10:00 a.m. | **Symposia:**
|               | Inhibition of PCSK9 in Dyslipidemia Patients with Diabetes
|               | 2017 Updates on Charcot Neuroarthropathy
|               | New Learnings from the Results of the Liraglutide Effect and Action in Diabetes—Evaluation of Cardiovascular Outcome Results (LEADER) Trial
|               | **Symposium**
|               | NDEP Symposium—Shared Decision-Making—Strategies for Improvements in Patient-Provider Communication
|               | Oral Presentations
| 10:15 a.m.—11:45 a.m. | President, Medicine & Science Address and Banting Medal for Scientific Achievement
| 12:00 p.m.—1:00 p.m. | **Professional Interest Group Session**
|               | Making the Connection—Male Hypogonadism, Testosterone Replacement, and Diabetes
| 12:00 p.m.—1:00 p.m. | **Professional Interest Group Session**
|               | Joint Position Statement on the Use of Language in Diabetes—Why Language Matters
|               | Building Capacity in Psychosocial Care of People with Diabetes—Action Steps following the Release of the ADA Psychosocial Position Statement
| 12:00 p.m.—1:00 p.m. | **Professional Interest Group Session**
|               | Staging Presymptomatic Type 1 Diabetes—Is There Enough Evidence?
| 12:00 p.m.—1:00 p.m. | General Poster Session/Moderated Poster Discussions

**Additional Information:**
- **Registration Hours:** 7:30 a.m.—5:00 p.m.
- **Shop Diabetes Store Hours:** 7:30 a.m.—6:45 p.m.
- **Exhibit Hall Hours:** 10:00 a.m.—4:00 p.m.
- **Poster Hall Hours:** 7:30 a.m.—6:30 p.m.
**D A Y- A T- A- G L A N C E S C H E D U L E**
**S U N D A Y, J U N E 1 1—W E A R R E D D A Y (C O N T I N U E D)**

<table>
<thead>
<tr>
<th>Time</th>
<th>Acute and Chronic Complications</th>
<th>Behavioral Medicine, Clinical Nutrition, Education, and Exercise</th>
<th>Clinical Diabetes/Therapeutics</th>
<th>Epidemiology/Genetics</th>
<th>Immunology/Transplantation</th>
<th>Insulin Action/Molecular Metabolism</th>
<th>Integrated Physiology/Obesity</th>
<th>Islet Biology/Insulin Secretion</th>
</tr>
</thead>
<tbody>
<tr>
<td>2:15 p.m.—4:15 p.m.</td>
<td>Symposium Physiology of Nervous System, Detection of Hypoglycemia</td>
<td>Symposium Exercise and Diabetes Complications</td>
<td>Current Issues Should Continuous Glucose Monitoring Be Prescribed for People with Type 2 Diabetes? A Pro/Con Discussion</td>
<td>(2:15 p.m.—3:00 p.m.) Kelly West Award for Outstanding Achievement in Epidemiology Lecture</td>
<td>Oral Presentations</td>
<td>Symposium Cell Signaling in the Central Nervous System as a Mediator of Disease</td>
<td>Symposium Factors Influencing Epigenetic Plasticity in the Development of Type 2 Diabetes Mellitus</td>
<td>Symposium Beta-Cell Maturation</td>
</tr>
<tr>
<td></td>
<td>Oral Presentations</td>
<td></td>
<td>Symposia Pharmacologic Strategies in Diverse Populations</td>
<td>Results of the JDRF Reducing with Metformin Vascular Adverse Lesions in Type 1 Diabetes (REMOVAL) International Multicenter Trial</td>
<td>Oral Presentations</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Edwin Bierman Award Lecture</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4:30 p.m.—6:30 p.m.</td>
<td>Symposium Joint ADA/ASN Symposium—Effects of New Diabetic Treatments on Diabetic Kidney Disease</td>
<td>Symposium Patient-Reported Outcomes (PROs)—Using Clinic-Based Screening and Intervention to Inform Diabetes Care</td>
<td>Symposium What’s New in Insulin-Related Therapy? Global Therapeutic Challenges and Solutions in Diabetes Care</td>
<td>Symposium Gene Expression and Genome Regulation in Islets and Kidney</td>
<td>Oral Presentations</td>
<td>Symposium Technical Innovations in Islet Transplantation—Novel Approaches</td>
<td>Oral Presentations</td>
<td>Symposium Liver Fat and Metabolic Function—Obesity, Gene, and Gut Interactions</td>
</tr>
<tr>
<td></td>
<td>Oral Presentations</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Event</td>
<td>Location</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>--------------</td>
<td>----------------------------------------------------------------------</td>
<td>------------------------</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8:00 a.m. — 10:00 a.m.</td>
<td>Symposium: Healthy Lifestyle Matters for Patients with Diabetes and Kidney Disease</td>
<td>Acute and Chronic Complications</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Oral Presentations</td>
<td>Behavioral Medicine, Clinical Nutrition, Education, and Exercise</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Symposium: Personalized Nutrition — Nutrigenetics, Nutrigenomics — Relevance to Diabetes</td>
<td>Clinical Diabetes/ Therapeutics</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Oral Presentations</td>
<td>Epidemiology/ Genetics</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:15 a.m. — 11:45 a.m.</td>
<td>National Scientific &amp; Health Care Achievement Awards Presentation and Outstanding Scientific Achievement Award Lecture</td>
<td>Exhibit Hall</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:00 p.m. — 1:00 p.m.</td>
<td>Professional Interest Group Sessions: Patient-Centeredness in Diabetes Research — Methodology and Opportunities</td>
<td>Professional Interest Group Sessions</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Professional Interest Group Session: To Screen or Not to Screen for Diabetes</td>
<td>Professional Interest Group Session</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Professional Interest Group Session: T-Cell Specificities in Initial Disease and Recurrent Disease after Pancreas or Islet Transplantation</td>
<td>Professional Interest Group Session</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:00 p.m. — 1:00 p.m.</td>
<td>General Poster Session/Moderated Poster Discussions</td>
<td>General Poster Session/Moderated Poster Discussions</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Acute and Chronic Complications</td>
<td>Behavioral Medicine, Clinical Nutrition, Education, and Exercise</td>
<td>Clinical Diabetes/Therapeutics</td>
<td>Epidemiology/Genetics</td>
<td>Immunology/Transplantation</td>
<td>Insulin Action/Molecular Metabolism</td>
<td>Integrated Physiology/Obesity</td>
<td>Islet Biology/Insulin Secretion</td>
</tr>
<tr>
<td>--------------</td>
<td>---------------------------------</td>
<td>---------------------------------------------------------------</td>
<td>---------------------------------</td>
<td>-----------------------</td>
<td>-----------------------------</td>
<td>-----------------------------------</td>
<td>-------------------------------</td>
<td>---------------------------------</td>
</tr>
<tr>
<td>2:15 p.m.—4:15 p.m.</td>
<td>Case Studies Case-Based Management of Neuropathies</td>
<td>Symposia Cognitive Functioning and Decision-Making in Diabetes</td>
<td>Symposium (2:15 p.m.—3:15 p.m.) Cardiovascular Safety of Insulin Degludec vs. Insulin Glargine in Patients with Type 2 Diabetes at High Risk of Cardiovascular Events (DEVOTE)</td>
<td>Symposium Genetic Evidence for Causal Relationships in Diabetes</td>
<td>Oral Presentations</td>
<td>Oral Presentations</td>
<td>Symposium Antidiabetic Actions of Leptin in Insulin-Deficient Animal Models</td>
<td>Oral Presentations</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
**D Ay-at-a-gLAnce ScHeDuLe**  
**tuErn, juNe 13**

<table>
<thead>
<tr>
<th>Time</th>
<th>Acute and Chronic Complications</th>
<th>Behavioral Medicine, Clinical Nutrition, Education, and Exercise</th>
<th>Clinical Diabetes/Therapeutics</th>
<th>Epidemiology/Genetics</th>
<th>Immunology/Transplantation</th>
<th>Insulin Action/Molecular Metabolism</th>
<th>Integrated Physiology/Obesity</th>
<th>Islet Biology/Insulin Secretion</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:30 a.m.—9:30 a.m.</td>
<td>Symposium Hypoglycemic-Associated Autonomic Failure (HAAF) in Diabetes Revisited</td>
<td>Symposium Cognitive Decline—Recognizing and Adapting Diabetes Care Strategies</td>
<td>Symposium Pediatric Diabetes and Associated Comorbidities</td>
<td>Symposium Prediabetes—Are We Missing Opportunities for Intervention and Risk Reduction?</td>
<td>Symposium Mechanistic Role of Metabolic Markers in Insulin Action</td>
<td>Current Issues A Modern Update of Thrifty Genes, Set Points, and Other Models of Obesity Pathogenesis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>9:45 a.m.—11:45 a.m.</td>
<td>Oral Presentations ADA Presidents Oral Session</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
11:30 a.m.-12:30 p.m.

**Mini-Symposia**

- **Clinical Innovation in Vision**
  
  Nondamaging Retinal Laser Therapy of the Macula
  Daniel Palanker, PhD
  Update on the Latest Pharmacological Therapies
  Baruch D. Kuppermann, MD, PhD
  Question and Discussion Period

- **Exercise for Type 1 Diabetes**
  
  Exercise and the Development of the Artificial Pancreas
  Michael C. Riddell, PhD
  Mechanisms Regulating Glucose Metabolism During and After Exercise in Type 1 Diabetes
  Pietro Galassetti, MD, PhD
  Question and Discussion Period

- **The Stigma of Diabetes—An Underappreciated Reality**
  
  The Developed-Country Perspective
  Susan J. Guzman, PhD
  The Emerging-Country Perspective
  Lindsay M. Jaacks, PhD
  Question and Discussion Period

- **Provocative Therapies and Clinical Technologies**
  
  The SPRING Trial—a Randomized Control Trial of Probiotics
  Marcelle Callaway, MBBS (Hons 1), FRACP, PhD, GCELead
  The CONCEPTT Trial—Continuous Glucose Monitoring in Women with Type 1 Diabetes
  Denice S. Feig, MD, MSc, FRCPC
  Question and Discussion Period

- **Big Data, Small Data, and Type 1 Diabetes—Practice Redesign at the Intersection of Families, Providers, Value-Based Reimbursement, and Technology**
  
  The Physician’s Perspective—Engaging Children and Families in Remote Monitoring as a Disease Management Strategy
  Laura M. Gandrud, MD
  Findings from the Field—Results of a Randomized Pilot Study of Intensive Remote Monitoring among Children with Type 1 Diabetes
  Aylin E. Altan, PhD
  Question and Discussion Period

- **A Researcher’s Guide to Exploring Diabetes Genetic Data in the Type 2 Diabetes Knowledge Portal**
  
  Data, Analysis, and Tools in the Type 2 Diabetes Knowledge Portal
  Noël Burtt, PhD
  Demonstration of Questions that Can Be Addressed Using the Portal
  Jason A. Flannick, PhD
  Question and Discussion Period

- **The Future Face of Diabetes Care—Beta-Cell Replacement vs. Technology**
  
  The Future of Diabetes Management Is Closed-Loop Pump Technology
  Jeffrey R. Millman, PhD
  The Future of Diabetes Management Is Cell Replacement Therapy
  Aaron J. Kowalski, PhD
  Question and Discussion Period

- **The Light and Dark Sides of Circadian Metabolic Regulation**
  
  Good Times for Transcriptional Regulation of Liver Metabolism
  Mitchell A. Lazar, MD, PhD
  Question and Discussion Period

**12:45 p.m.-1:45 p.m.**

**Mini-Symposia**

- **Translational Science and Diabetic Foot Ulceration (DFU)—The Pathway from the Biomechanics Lab to Clinical Practice**
  
  2017 Updates on Technology and Advances in DFU Prevention
  Metin Yavuz, DEng
  Applying Technology in the Clinical Setting—Is It Practical?
  Lawrence A. Lavery, DPM, MPH
  Question and Discussion Period

- **Managing Diabetic Neuropathy—Science or Art?**
  
  Genetics and the Quest for Novel Therapies in Painful Diabetic Neuropathy
  Hsinlin T. Cheng, MD, PhD
  The New ADA Consensus Guidelines on Diabetic Peripheral Neuropathy—Will They Change Your Practice?
  Eva L. Feldman, MD, PhD
  Question and Discussion Period

- **International Guidelines Regarding Nutrition for Preschoolers with Type 1 Diabetes**
  
  International Perspective
  Carmel E.M. Smart, RD, PhD
  Perspective from the United States
  Laurie A. Higgins, MS, RD, LDN, CDE
  Question and Discussion Period

- **What’s App? Opportunities and Challenges in Diabetes Mobile Technologies**
  
  Translating Behavioral Science for mHealth Systems
  Shelagh A. Mulvaney, PhD
  Day-to-Data—Experiences of Patients and Families with Diabetes Data
  Sara Krugman
  Question and Discussion Period

Speakers and presentation titles are subject to change.
• New Therapies for Diabetes in Youth—What the Future May Bring
  Disease-Modifying Therapies in Type 1 Diabetes
  Carla J. Greenbaum, MD
  Beyond Metformin in Type 2 Diabetes
  Philip S. Zeitler, MD, PhD
  Question and Discussion Period

• Sulfonylureas—Should I Stay or Should I Go?
  Do They Have a Role in the Contemporary Treatment of Type 2 Diabetes?
  Kamlesh Khunti, PhD, MD, FRCP, FMedSci
  Question and Discussion Period

• The History of the ADA Guidelines—Their Influence on the Study of and Clinical Practice in Complications in Type 1 and Type 2 Diabetes
  The ADA Guidelines’ Influence on the Study of Complications in Type 1 and Type 2 Diabetes
  Jill P. Crandall, MD
  The ADA Guidelines’ Influence on the Clinical Practice of Type 1 and Type 2 Diabetes
  Maria F. Lopes-Virella, MD, PhD
  Question and Discussion Period

• Biomarkers of Type 1 Diabetes
  Biomarkers of Disease Progression and Efficacy/Treatment in Type 1 Diabetes
  Massimo Pietropaolo, MD
  Question and Discussion Period

• Human Islet Research Network—NIH-Funded Interactive Research Network
  Consortium on Beta-Cell Death and Survival—Biomarkers to Identify Type 1 Diabetes Progression
  Carmella Evans-Molina, MD, PhD
  Consortium on Modeling Autoimmune Interactions—Modeling the Interaction between Islets and the Immune System
  Dale Greiner, PhD
  Question and Discussion Period

2:00 p.m.-4:00 p.m.

Symposia
• Update on Cardiovascular Outcomes Trials (CVOTs)
  Cardiovascular Outcomes with Semaglutide in Subjects with Type 2 Diabetes Mellitus (SUSTAIN 6)
  Tina Vilsbøll, MD, DMSc
  Rethinking CVOTs in Diabetes—What Should the Future Hold?
  Lawrence Leiter, MD, FRCPC, FACP, FACE, FAHA
  Translating CVOTs Data into Clinical Practice—Cost Effectiveness of Newer Therapies
  Amanda I. Adler, MD, PhD, FRCP
  Translating CVOTs Data into Clinical Practice—Should the Guidelines Change?
  Anne Peters, MD

• If You Build It, They Will Come—But Will They Stay? Recruitment and Retention in Diabetes Trials
  Use of Financial Incentives for Patient Engagement
  Robert W. Jeffery, PhD
  Recruiting and Retaining Rural, Minority, and Underserved Populations in Behavior Change Intervention
  Doyle M. Cummings, PharmD
  Maximizing Recruitment and Retention in Randomized Controlled Trials for Pediatric Diabetes
  Randi Streisand, PhD
  Leveraging Technology in Lifestyle Interventions
  Sherry Pagoto, PhD

• Hypoglycemia Prediction Models for Risk Stratification—Prediction to Prevention
  How Can Prediction Models Help Tailor Individual and Population Care?
  Michael J. Pencina, PhD
  VA Hypoglycemia Prediction Model
  Donald R. Miller, ScD
  Kaiser Permanente Hypoglycemia Prediction Model
  Andrew J. Karter, PhD
  Johns Hopkins Real-Time Model of Inpatient Insulin-Associated Hypoglycemia
  Nestoras N. Mathioudakis, MD, MHS
  Panel Discussion

• Diabetes Care for Older Adults
  Diabetes Care in the Older Patient—Clinical Care Issues
  Graydon S. Meneilly, MD, FRCPC, MACP
  Cardiovascular Disease Impact and Prevention
  Jeffrey B. Halter, MD
  Benefits and Harms of More Aggressive Glycemic Treatment in Older Adults
  Sei J. Lee, MD, MAS
  Hypoglycemia in the Older Patient with Type 1 Diabetes
  Ruth S. Weinstock, MD, PhD

• mHealth—Friend or Bystander in Diabetes Management?
  mHealth—Successes and Failures in Chronic Disease Management
  Emily Seto, PhD, PEng
  mHealth—Successes and Failures in Health Promotion
  Seth S. Martin, MD, MHS
  Mobile Technologies for Data Collection
  Mark A. Clements, MD, PhD
  What to Make of Big Patient Data?
  Christopher Hane, PhD
Primer on Transplantation for the Clinician
Approach to the Patient with Recurrent Severe Hypoglycemia—What Is the Role of Transplant?
Pratik Choudhary, MD, MBBS, FRCP

Approach to the Patient with Diabetic Nephropathy—When to Consider Pancreas/Islet Transplant
Jennifer L. Larsen, MD

Addressing Hyperglycemia after Transplantation—From Posttransplant Diabetes to Recurrence of Hyperglycemia after Islet/Pancreas Transplant
Mark E. Molitch, MD

Psychosocial Aspects of Islet/Pancreas Transplant
Jane Speight, MSc, PhD, CPsychol, AFbPsS

Management of the Patient after Total Pancreatectomy with Islet Autotransplant
Betul Hatipoglu, MD

Question and Discussion Period

Big Data and Generating Novel Hypotheses
The Genetic Architecture of Obesity and Diabetes
Alan Attie, PhD

Metabolomics and the Redox Basis of Biomarkers of Insulin Resistance
Russell P. Goodman, MD, DPhil

Gut Microbes and Luminal Dynamics in Health and Disease
Amir Zarrinpar, MD, PhD

Applying Metabolomics to Identify New Biomarkers
Daniel K. Nomura, PhD

The Role of the Intestinal Immune System in Metabolic Disease
Blood Glucose Influences Outcomes from Intestinal Pathogens
Jonathan D. Schertzer, PhD

Rational Design of Probiotics to Manipulate Gut Microbiota–Bile-Host Dynamics
Casey M. Theriot, PhD

Resident Macrophage Cometabolites of Hepatocytes Modulate Hepatic Fibrosis
Peter A. Crawford, MD, PhD

Manipulating the Microbiome to Treat Metabolic Disease
Sean S. Davies, PhD

Chemical Modulation of Beta-Cell Function
Drug Discovery in hESC-Derived Beta Cells
Shuibing Chen, PhD

Chemical Modulators of Beta-Cell Signaling and Proliferation
Andrew F. Stewart, MD

DyRK1a Inhibition Stimulates Beta-Cell Proliferation
Bridget K. Wagner, PhD

Signals that Regulate Beta-Cell Differentiation and Beta-Cell Mass
Shoen Kume, PhD

A Heavy Heart—Metals, Diabetes, and Cardiovascular Disease Outcomes
Introduction
David M. Nathan, MD

Type 2 Diabetes and Residual Risk following Acute Myocardial Infarction—Still There after All These Years
Mikhail N. Kosiborod, MD

Metals, Diabetes, and Cardiovascular Risk—From Mechanisms to Epidemiology
Ana Navas-Acien, MD, PhD

Benefits of Metal Chelation on Cardiovascular Risk in Patients with Diabetes—Is There a New Treatment Strategy on the Horizon?
Gervasio A. Lamas, MD

Question and Discussion Period

SGLT2 Inhibitors—Still More to Explore
SGLT2 Inhibitors, Diabetic Ketoacidosis, and the Kidney
Matthew R. Weir, MD

The SGLT2-Glucagon Connection
Richard G. Kibbey, MD, PhD

Clinical Impact of SGLT2 Inhibitors on Bone—The FDA Perspective
Lisa Yanoff, MD

Clinical Role of SGLT2 Inhibitors—Current and Future
Julio Rosenstock, MD

Can “Omic” and Genome-Wide Association Studies (GWAS) Reveal Therapeutic Links between Type 1 and Type 2 Diabetes?
GWAS and Inflammation/Beta-Cell Failure
Stephen S. Rich, PhD, FAHA

Microbiome in Type 1 and Type 2 Diabetes
Alexander Chervonsky, MD, PhD

Metabolomic Links between Type 1 and Type 2 Diabetes
Flemming Pociot, MD, DMSc

Question and Discussion Period

Oral Presentations
6:30 p.m.-8:30 p.m.

• ADA Networking Reception
SATURDAY, JUNE 10

8:00 a.m.-10:00 a.m.

Symposia

• Thirty-Year Anniversary of the Foot Care Interest Group—The Diabetic Foot, Then and Now
  Developments in Diabetic Foot Treatment over the Last 30 Years
  Andrew J.M. Boulton, MD, DSc (Hon), FACP, FRCP
  Then and Now—Progression in Our Understanding of the Charcot Foot
  Dane K. Wukich, MD
  Then and Now—Developments in the Diagnosis and Management of Diabetic Foot Infections and Osteomyelitis
  Benjamin A. Lipsky, MD, FACP, FIDSA, FRCP, FRCPS (Glasg)
  Stepping into the Future—The Diabetic Foot in the Next 30 Years
  David G. Armstrong, DPM, MD, PhD

• ADA Diabetes Care Symposium—Diabetes Care and Research through the Ages
  Opening Remarks
  William T. Cefalu, MD
  A Look Back as to How We Got Here
  Jay S. Skyler, MD, MACP
  Current Treatment Paradigms Today—How Well Are We Doing?
  Bernard Zinman, CM, MD, FRCP, FACCP
  Evolving Concepts and Future Directions for Cardiovascular Outcomes Trials
  Matthew C. Riddle, MD
  Presentation of “Profiles in Progress” Plaques
  William T. Cefalu, MD
  What Does the Future Hold?
  Ele Ferrannini, MD
  Panel Discussion

• ADA Education Recognition Program Symposium—Introduction to the 2017 National Standards for Diabetes Self-Management Education and Support
  The Revised National Standards for Diabetes Self-Management Education and Support (Standards 1-5)
  Joni Beck, PharmD, BC-ADM, CDE
  The Revised National Standards for Diabetes Self-Management Education and Support (Standards 6-10)
  Deborah A. Greenwood, PhD, RN, CNS, BC-ADM, CDE, FAFADE

• Oral Presentations
  • Vivian Fonseca Scholar Award Presentation
    Kishwar Azad, MRCS, LRCP, FCPS, MSc, Hon FRCPCH

10:15 a.m.-11:15 a.m.

• President, Health Care & Education Address
  Brenda Montgomery, RN, MSHS, CDE

• Outstanding Educator in Diabetes Award Lecture
  Davida F. Kruger, MSN, APRN-BC, BC-ADM
11:30 a.m.-12:30 p.m.

Professional Interest Group Sessions

• Hyperbaric Oxygen Therapy for Diabetic Foot Ulcers (DFUs)—Fact or Fiction?
  The Facts to Support Hyperbaric Oxygen Therapy in DFU Treatment
  William H. Tettelbach, MD
  The Argument against Hyperbaric Oxygen Therapy in DFU Treatment
  Andrew J.M. Boulton, MD, DSc (Hon), FACP, FRCP

• Eating Behaviors in Type 1 Diabetes
  Panel Discussion
  Ann E. Goebel-Fabbri, PhD
  Kyle S. Burger, MPH, RD, PhD

• The New Physical Activity/Exercise Guidelines for Diabetes
  The New Physical Activity/Exercise Guidelines for Diabetes
  Sheri R. Colberg, PhD, FACSM

General Poster Session

11:30 a.m.-1:30 p.m.

Moderated Poster Discussions

1:45 p.m.-3:45 p.m.

Symposia

• Diabetes, Drugs, and Heart Failure
  Natural History, Manifestations, and Mechanics of Heart Failure in Diabetes
  Shannon M. Dunlay, MD, MS
  Impact of New Diabetes Medications on Heart Failure Risk
  Eldrin F. Lewis, MD, MPH
  Mechanisms Linking Diabetes Therapies and Heart Failure
  E. Dale Abel, MD, PhD
  Optimizing Care of the Patient with Diabetes and Heart Failure
  Jacob A. Udell, MD, MPH, FRCPC

• The New Psychosocial Position Statement from the ADA—Implications for Practice (With Richard R. Rubin Award Lecture)
  Richard R. Rubin Award Lecture—Your Exclusion, My Inclusion—Treating the Most Challenging in Diabetes
  Michael A. Harris, PhD
  The ADA Psychosocial Position Statement—Ideas Whose Time Has Come
  William H. Herman, MD, MPH
  Recommendations for the Psychosocial Care of People with Diabetes—An Overview
  Mark F. Peyrot, PhD
  Integrated Person-Based Team Care—Roles, Resources, and Optimizing Outcomes
  Deborah Young-Hyman, PhD
  Using and Understanding Screening Measures
  Mary K. de Groot, PhD
  Psychosocial Position Statement—Pathways to Implementation
  Felicia Hill-Briggs, PhD, ABPP

• Reducing Hospital Readmissions—Effective Transitions Matter
  Diabetes Readmissions—The Pervasive and Costly Realities
  Daniel J. Rubin, MD, MSc, FACE
  Transitional Care Model—Improving Diabetes Outcomes for Vulnerable Populations
  Mary D. Naylor, PhD, RN, FAAN
  Hospital-Based Care Influences Outpatient Success—Leveraging the Hospital Admissions or Emergency Department Visits
  Carine M. Nassar, MS, RD, CDE
  Getting Off the Merry-Go-Round—Strategies to Reduce Readmissions
  Kristen Kulasa, MD

• Overtreatment in Diabetes Management
  The Science of Personalized Diabetes Management—Do Benefits of Glycemic Therapy Vary among Different Patients?
  Sandeep Vijan, MD, MS
  Too Much of a Good Thing—What Happens When Treatment Goes Too Far?
  Rozalina G. McCoy, MD, MS
  The Art of Personalized Diabetes Care—How Do Providers Individualize Treatment in the Real World?
  Deborah J. Wexler, MD
  Supporting Personalized Patient-Centered Care through Shared Decision-Making
  Elbert S. Huang, MD, MPH, FACP

• Joint ADA/ISPAD Symposium—Current Status of Complications in Youth with Type 1 Diabetes
  Update on Retinopathy—Should We Screen or Not?
  Kim C. Donaghue, MBBS, PhD, FRACP
  Update on Nephropathy—When Should We Treat?
  David B. Dunger, MD
  Update on Macrovascular Disease and Risk Factors—Time to Be More Aggressive with Treatment?
  David M. Maahs, MD, PhD
  Update on Neuropathy—The Forgotten Complication
  Eva L. Feldman, MD, PhD

• Into the Endocrine Bowels of Diabetes
  The Gut and Glucose Homeostasis—Overview of the Interplay
  Jens Juul Holst, MD, PhD
  The Upper Gut and Diabetes
  Christopher K. Rayner, MBBS, PhD
  The Incretin Effect—From the Last 30 Years to the Next 30!
  Michael A. Nauck, MD
  Metabolic Surgery of the Gut in the Treatment of Diabetes
  Nancy Puzziferri, MD, MSCS
• Dealing with the Rising Costs of Insulin—An Active Dialogue
The Rising Costs of Insulin—Introduction and Historical Perspective
Kasia J. Lipska, MD
Understanding the Players in the Rising Costs of Insulin
Alan Carter, PharmD
Clinical Decision-Making in a Cost-Conscious Era
David C. Robbins, MD
Paving the Way Forward
Robert E. Ratner, MD

• Genome Editing in Islet Biology and Disease
CRISPR Methods to Control Gene Expression
Timothy E. Reddy, PhD
Genome Editing to Link Regulatory Variants to Disease Phenotypes
Maike Sander, MD
Editing Patient Mutations to Assess Genetic Variant Function
Nicola L. Beer, PhD
Editing of Neonatal Diabetes iPS Cells
Timo Otonkoski, MD, PhD

• Therapies to Preserve Beta Cells in Type 1 Diabetes
Therapy for Type 1 Diabetes—Short Treatment for Durable Benefit
Gerald T. Nepom, MD, PhD
Disease-Specific Therapy (Antigen-Specific Immunotherapy)
Carolin Daniel, PhD
Crossover Therapy from other Autoimmune Diseases
Jane H. Buckner, MD
Question and Discussion Period

• Insulin Action and Cellular Metabolism
MondoA—Skeletal Muscle Metabolism and Insulin Sensitivity
Daniel P. Kelly, MD
ACOT1—A Branch Point in Fatty Acid Signaling and Oxidative Metabolism
Douglas G. Mashek, PhD
Life without Mitochondrial Fatty Acid Oxidation
Michael J. Wolfgang, PhD
Liver Insulin Signaling and the Regulation of Lipogenesis
Sudha Biddinger, MD, PhD

• The Good and the Bad of Glucagon Physiology and Therapeutics
Glucagon Metabolism and Pathophysiology in Diabetes
Rita Basu, MD
Glucagon-Based Therapeutics in Obesity and Diabetes
Melanie J. Davies, CBE, MB, ChB, MRCP, MD, FRCP
Glucagon and the Multihormone Artificial Pancreas
Ananda Basu, MBBS, MD, FRCP

• ADA Pathway to Stop Diabetes Symposium
Nanoparticle Delivery System Modulates Local Gene Expression to Accelerate Diabetic Tissue Regeneration
Daniel J. Ceradini, MD
Astrocyte IKK/NF-kB Signaling Is Required for Diet-Induced Obesity
Joshua P. Thaler, MD, PhD
The Role of MicroRNAs in Intestinal Stem-Cell Dysfunction Associated with Diet-Induced Obesity
Praveen Sethupathy, PhD
Maternal Gestational Diabetes and Pre-pregnancy BMI Are Independently Associated with Central Adiposity in Children
Kathleen A. Page, MD
A New Role for the BCKDH Kinase and Phosphatase in Glucose and Lipid Metabolism
Phillip J. White, PhD
H202-Responsive Vesicles Integrated with Transcutaneous Patches for Glucose-Mediated Insulin Delivery
Zhen Gu, PhD

Oral Presentations
• Roger Pecoraro Award Lecture
Dane K. Wukich, MD
4:00 p.m.-6:00 p.m.
Symposia
• The Atherogenic Dyslipidemia Complex—New Biomarkers and Therapies Beyond LDL
Update on the Atherogenic Dyslipidemia Complex
Henry N. Ginsberg, MD
High-Density Lipoproteins—What We’ve Learned and Where We’re Headed
Alan T. Remaley, MD, PhD
Can Novel Biomarkers and Testing Help Unravel the Complexity of the Atherogenic Dyslipidemia Complex and Guide Therapy?
Christie M. Ballantyne, MD
New Therapies for Old Lipoprotein Players (i.e., Lp(a), Triglycerides, and Apo C)
Joseph L. Witztum, MD

• Population Health, Affordable Care Act (ACA), and New Approaches for Dissemination/Implementation of the Diabetes Prevention Program (DPP)
Policy Update—Impact of ACA and Medicare on Dissemination and Implementation of the DPP
Nina C. Brown-Ashford, MPH, CHES
Identifying and Overcoming Barriers to Enrollment in the DPP
Nicole Johnson, DrPH, MPH, MA
“Tales from the Trenches”—Rolling Out the DPP in Montana, 2008-2017
Dorothy Gohdes, MD
“Tales from the Trenches”—Recruitment and Retention in the DPP
Linda Weiss, PhD
• Exercise-Regulated Molecular Transducers of Insulin Resistance
Role of Rac1 in Skeletal Muscle Glucose Uptake
Lykke Sylow, PhD
Paradoxical Role of AMPK in Skeletal Muscle Insulin Resistance
Louise Lantier, PhD
SNARK Regulation of Skeletal Muscle in Diabetes and Obesity
Sarah J. Lessard, PhD
AMPK, Exercise, and Insulin Sensitivity
TBD

• Harnessing the Power of Digital Connectivity in Sickness and in Health
Welcome to the New Era of Digital Health
Robert B. McCray, BS, JD
Regulatory Perspectives on Health Apps for the Management of Diabetes—Perspective from CDC
Bakul Patel, MS, MBA
New Research—Perspectives from NIH
Judith E. Fradkin, MD
What Are the Gaps in Diabetes Digital-Health Research?
Charlene C. Quinn, PhD, RN

• Bariatric Surgery in Special Populations
Update on Bariatric Surgery
Daniel B. Jones, MD, MS, FACS
Bariatric Surgery in Youth
Thomas H. Inge, MD, PhD
Bariatric Surgery in Patients with a BMI <35 kg/m²
Wei-Jei Lee, MD, PhD
Bariatric Surgery in Type 1 Diabetes
Sangeeta R. Kashyap, MD

• Sleep and Diabetes—What’s the Link, and What Can We Do about It?
Overview—The Epidemiology of Sleep and Diabetes
Kristen L. Knutson, PhD
Circadian Physiology and Glucose Homeostasis
Kenneth P. Wright, Jr, PhD
Mechanisms Linking Insufficient Sleep to Diabetes
Esra Tasali, MD
Treatment Options for Sleep—Continuous Positive Airway Pressure and Beyond
Naresh M. Punjabi, MD, PhD

• Beta Cells Under Attack—Lessons from Transplantation for New-Onset Type 1 Diabetes
Addressing Cellular Immunity—Transplant Therapies Applied to New-Onset Type 1 Diabetes
Antoinette Moran, MD
Protecting the Beta Cell from Innate Immunity
Lorenzo Piemonti, MD
Beta-Cell Biomarkers—Assessing Islet Loss in Transplant and Type 1 Diabetes
Kevan C. Herold, MD
Lessons from Islet Physiology—Plasticity of Islet-Cell Function
Patrick E. MacDonald, PhD

• System-Based Approaches to Obesity Pathogenesis
Global Analysis of Enzyme Function in the Study of Energy and Metabolic Homeostasis
Enrique Saez, PhD
Genetic Dissection of Obesity-Related Traits Using Systems Approaches in Mice
Aldons J. Lusis, PhD
The Convergence of Systems and Reductionist Approaches in Obesity-Related Traits
Mete Civelek, PhD
Epigenetic Modulation of Metabolic Decisions in the Pathogenesis of Obesity
Andrew Pospisilik, PhD

• Novel Islet Signaling Pathways
ChREBP Isoforms and Beta-Cell Proliferation
Donald K. Scott, PhD
Signaling Mechanisms of the Fatty Acid Receptor GPR40
Vincent Poitout, DVM, PhD
Sorcin Links Beta-Cell Lipotoxicity to ER Ca²⁺ Stores
Isabelle Leclerc, MD, PhD
Metabolic Dissection of Beta-Cell Protection through BH3 Mimicry
Nika N. Danial, PhD

Oral Presentations
• Norbert Freinkel Award Lecture
Gernot Desoye, PhD

SUNDAY, JUNE 11
WEAR RED DAY
8:00 a.m.-10:00 a.m.
Symposia
• Inhibition of PCSK9 in Dyslipidemia Patients with Diabetes
Lipid Management in Individuals with Diabetes at High Cardiovascular Risk—What Are the Unmet Needs?
Kausik K. Ray, MB, ChB, MD
PCSK9 and Diabetes
Bertrand Cariou, MD, PhD
ODYSSÉE DM Program—Design and Study Populations
Dirk Müller-Wieland, MD
Alirocumab and Insulin-Treated Diabetes—Insights from the ODYSSEY DM-INSULIN Study
Lawrence Leiter, MD, FRCP, FACC, FACE, FAHA
Alirocumab vs. Usual Care in Diabetes with Mixed Dyslipidemia—ODYSSÉE DM-DYSLIPIDEMIA Study
Robert R. Henry, MD
Independent Commentary
Henry N. Ginsberg, MD

• 2017 Updates on Charcot Neuroarthropathy
Overview on the Algorithm for Charcot Care
Lee C. Rogers, DPM
The Latest Developments on Charcot Pathogenesis
Nina L. Petrova, MD, PhD
Diagnostic Imaging of the Charcot Foot—Has Anything Changed in 2017?
Avneesh Chhabra, MD
Impact of Charcot on Health Care Costs and Resource Utilization
Jonathan Labovitz, DPM, FACP, FACM, CHCQM

• New Learnings from the Results of the Liraglutide Effect and Action in Diabetes—Evaluation of Cardiovascular Outcome Results (LEADER) Trial
Cardiovascular Outcomes in LEADER—Recap and New Analyses
Steven E. Nissen, MD, MACC
New Results—Long-Term Clinical and Metabolic Data
Richard E. Pratley, MD
New Results—Safety
Stephen C. Bain, MD
• NDEP Symposium—Shared Decision-Making—Strategies for Improvements in Patient–Provider Communication
  Shared Decision-Making—Why Does This Matter and What Do We Know?
  Linda M. Siminerio, RN, PhD, CDE
  Shared Decision-Making—Diabetes Risk Perceptions and Prevention
  Ann L. Albright, PhD, RD
  Shared Decision-Making and Vulnerable Populations—Social and Cultural Considerations
  Monica E. Peek, MD, MPH, MSc
  Shared Decision-Making in Pediatrics—Development and Evaluation of Web-Based Decision Aids for Candidates for Insulin Pump or Continuous Glucose Monitoring
  Tim Wysocki, PhD, ABPP
  Shared Decision-Making—Goal Setting and Treatment Choices When Evidence Is Ambiguous
  John B. Buse, MD, PhD
  Shared Decision-Making—Research Challenges and Opportunities
  Judith E. Fradkin, MD
  Shared Decision-Making “Then and Now”—Twenty Years of Diabetes Translation
  Linda M. Siminerio, RN, PhD, CDE
  Diane Tuncer, BS
  Judith A. McDivitt, PhD

• Joint ADA/AACC Symposium—The Role and Utility of Glycated Proteins—Beyond A1C
  Technical Challenges and Progress in the Measurement of Chronic Glycemia
  David B. Sacks, MB, ChB, FRCPath
  Is There a Clinical Need for Fructosamine or Glycated Albumin?
  Cyrus V. Desouza, MBBS
  Advanced Glycation End-Products—Do They Have a Role in Diabetes?
  Paul J. Thornalley, PhD
  Question and Discussion Period

• ADA Diabetes Symposium—Emerging Therapeutic Targets and Mechanisms of Action
  How Should We Think about the Role of the Brain in Glucose Homeostasis and Diabetes?
  Michael W. Schwartz, MD
  Single-Molecule Combinatorial Therapeutics for Obesity and Diabetes
  Matthias H. Tschöp, MD
  Mining the Genome for Therapeutic Targets
  Jose C. Florez, MD, PhD
  Question and Discussion Period

• Fail—The Islet Microenvironment and Type 1 Diabetes Initiation
  Pancreatic Beta-Cell Failure in Prediabetes
  Jay M. Sosenko, MD
  Proinflammatory Cytokines and Pancreatic Beta Cells—Death or Protection?
  John A. Corbett, PhD
  Intraislet Antigen-Presenting Cells Transiently Control T-Cell Pathogenesis
  Rachel S. Friedman, PhD
  Improper Responses of Islet Cells to Viruses
  Teresa Rodriguez-Calvo, DVM, PhD

• State of the Science—Molecular Transducers of Lifestyle Interventions to Health Benefits
  Molecular Mechanisms for the Health Benefits of Lifestyle Interventions—The Need for Knowledge
  Wendy M. Kohrt, PhD
  Molecular Transducers of Skeletal Muscle Adaptation
  Marcos M. Bamman, PhD
  Molecular Transducers of Adipose Tissue Adaptation
  Kristin I. Stanford, PhD
  Lifestyle Interventions and Brain Health
  Paul J. Laurienti, MD, PhD

• Aging and the Beta Cell
  Type 2 Diabetes Beta Cells Display Characteristics of Aging Beta Cells
  Klaus H. Kaestner, PhD
  The Effects of Placental Exosomes on Human Islets of Various Sex and Age
  Luc Baeyens, PhD
  Young Capillaries Rejuvenate Aged Islets
  Joana Almaca, PhD
  miRNAs and Age-Associated Decline of Islet Function
  Romano Regazzi, PhD

Oral Presentations
10:15 a.m.-11:45 a.m.

- President, Medicine & Science Address
  Alvin C. Powers, MD

- Banting Medal for Scientific Achievement
  Domenico Accili, MD

12:00 p.m.-1:00 p.m.

Professional Interest Group Sessions

- Making the Connection—Male Hypogonadism, Testosterone Replacement, and Diabetes
  Male Hypogonadism—Natural History and Prevalence in Men with Diabetes
  Ronald S. Swerdloff, MD
  Male Hypogonadism—Diagnostic Strategies and Challenges
  Christina C. Wang, MD, FRACP, FRCP
  Risks and Benefits of Testosterone Replacement in Men with Diabetes
  Elizabeth Barrett-Connor, MD

- Joint Position Statement on the Use of Language in Diabetes—Why Language Matters
  Real-Life Examples
  Jane K. Dickinson, RN, PhD, CDE
  Support from the Research
  Susan J. Guzman, PhD
  Recommendations for Practice
  Melinda D. Maryniuk, MEd, RD, CDE

- Building Capacity in Psychosocial Care of People with Diabetes—Action Steps following the Release of the ADA Psychosocial Position Statement
  Panel Discussion
  Korey K. Hood, PhD
  Jeffrey S. Gonzalez, PhD
  Alicia H. McAluliffe-Fogarty, PhD, CPsychol

- Staging Presymptomatic Type 1 Diabetes—Is There Enough Evidence?
  The Time Has Come to Stage Presymptomatic Type 1 Diabetes
  Richard A. Insel, MD
  It Is Premature to Stage Presymptomatic Type 1 Diabetes
  TBD
  Safe at School Updates
  Anastasia Albanese-O’Neill, PhD, ARNP, CDE
  Henry Rodriguez, MD

General Poster Session/Moderated Poster Discussions

2:15 p.m.-3:00 p.m.

- Kelly West Award for Outstanding Achievement in Epidemiology Lecture
  Dana Dabelea, MD, PhD

2:15 p.m.-4:15 p.m.

Current Issues

- Should Continuous Glucose Monitoring Be Prescribed for People with Type 2 Diabetes? A Pro/Con Discussion
  For People with Type 2 Diabetes on Intensive Insulin Therapy?
  Jeremy Pettus, MD
  Of Course, This Is a Great Idea!
  Well, Maybe So, But Not for Everyone
  William H. Polonsky, PhD, CDE
  For People with Type 2 Diabetes on Basal Insulin Therapy?
  Likely to Be of Significant Benefit
  Jeremy Pettus, MD
  Let’s Consider the Psychological Burden
  William H. Polonsky, PhD, CDE
  For People with Type 2 Diabetes Not Using Insulin?
  Might Be a Waste of Time
  Jeremy Pettus, MD
  If Done Right, This Could Be Terrific!
  William H. Polonsky, PhD, CDE

Symposia

- Physiology of Nervous System Detection of Hypoglycemia
  Brain Glucose Sensing Neurons in Hypoglycemia Detection
  Vanessa H. Routh, PhD
  Role of Astrocytes in the Central Nervous System Response to Hypoglycemia
  David H. McDougal, PhD
  Leptin-Regulated Neurons and Counterregulatory Response to Hypoglycemia
  Jonathan N. Flak, PhD
  Peripheral Hypoglycemic Detection at the Portal-Mesenteric Vein
  Casey Donovan, PhD

- Exercise and Diabetes Complications
  Exercise Interventions in Patients with Diabetes and Peripheral Artery Disease
  Mary McGrae McDermott, MD
  Exercise Performance in Adults with Type 2 Diabetes and Peripheral Neuropathy
  Patricia M. Kluding, PT, PhD
  Cardiorespiratory Fitness and Health Outcome in Type 2 Diabetes
  Peter Kokkinos, PhD

- Pharmacologic Strategies in Diverse Populations
  How Does Comparative Physiology Inform Treatment Approaches?
  Kieren J. Mather, MD
  Diabetes Treatment Approaches in Diverse Populations
  Mary Ann Banerji, MD, FACP
  Treatment Considerations in Nonobese Patients with Type 2 Diabetes
  Richard Arakaki, MD
  A Journey towards Precision Medicine in Diabetes
  Leif C. Groop, MD, PhD

- Results of the JDRF Reducing with Metformin Vascular Adverse Lesions in Type 1 Diabetes (REMOVAL) International Multicenter Trial
  Introduction, Study Rationale, and Design
  Helen M. Colhoun, MD
  Study Population
  Alicia J. Jenkins, MD
  Glycemia
  Irene M. Hramiak, MD, FRCP(C), FACP
  Primary Endpoint
  Nishi Chaturvedi, MD, MRCP
  Clinical and Metabolic Outcomes
  John R. Petrie, MB, ChB, PhD
  Retinal Outcomes
  Barbara E.K. Klein, MD, MPh
  Safety
  Martijn Brouwers, MD
  Conclusions
  Peter Rossing, MD, DMSc
  Perspective
  Naveed Sattar, MD, PhD
  Question and Discussion Period
• Cell Signaling in the Central Nervous System as a Mediator of Disease
  AMPK and Synaptic Plasticity in Neural Circuits Regulating Hunger
  Bradford B. Lowell, MD, PhD
  Regulation of Metabolism by the mTOR-Deptor Axis in the Brain
  Mathieu Laplante, PhD
  Endoplasmic Reticulum Stress Pathways in POMC Neurons and the Regulation of Metabolism
  Kevin W. Williams, PhD
  Brain Insulin Signaling and Cognitive Decline
  Suzanne M. de la Monte, MD, MPH

• Factors Influencing Epigenetic Plasticity in the Development of Type 2 Diabetes Mellitus
  Obesity and Epigenetic Plasticity
  Kartik Shankar, PhD
  Type 2 Diabetes Epigenetic Plasticity
  Adam R. Wende, PhD
  Diet and Epigenetic Plasticity
  Joseph H. Nadeau, PhD
  Developmental Programming of Physical Activity
  Robert A. Waterland, PhD

• Beta-Cell Maturation
  Metabolic Maturation of the Beta Cell
  Anil Bhushan, PhD
  Regulation of Stem Cell-Derived Beta-Cell Maturation
  Holger A. Russ, PhD
  Islet Pericytes Promote Beta-Cell Maturation
  Limor Landsman, PhD
  Prox1 Regulates Postnatal Beta-Cell Maturation
  Beatriz Sosa-Pineda, PhD

Oral Presentations

• Edwin Bierman Award Lecture
  Mark E. Cooper AO, MBBS, PhD, FRACP

4:30 p.m.-6:30 p.m.

Symposia

• Joint ADA/ASN Symposium—Effects of New Diabetic Treatments on Diabetic Kidney Disease
  SGLT2 Inhibitors
  David Cherney, MD, CM, PhD, FRCP(C)
  GLP-1 Receptor Agonists
  Katherine R. Tuttle, MD, FACP, FASN, FNFK
  DPP-4 Inhibitors
  Mark E. Cooper AO, MBBS, PhD, FRACP
  Insulin
  Mark E. Williams, MD, FACP, FASN

• Patient-Reported Outcomes (PROs)—Using Clinic-Based Screening and Intervention to Inform Diabetes Care
  Implementation of a Pediatric Screening Program
  Sarah D. Corathers, MD
  Adult Psychosocial Screening and Intervention—What Providers Need to Know
  Paul S. Ciechanowski, MD, MPH
  Cultural Considerations for Clinic-Based Screening and Intervention—Is That the Question?
  Jeffrey S. Gonzalez, PhD

• Using Technology to Improve Performance Outcomes and Care
  The Mobile Insulin Titration Intervention (MiTI) Program—Insulin Titration Using Text Messaging in Two New York City Safety-Net Clinics
  Natalie Levy, MD
  Technological Approaches to Achieve Pay-for-Performance Standards
  Athena Philis-Tsimikas, MD
  Incentive Payment Projects that Work
  Fareeha Siddiqui, MD, MPH
  Evaluating and Using Apps to Improve Health Care Provider Performance
  Brandon Arbiter

• What’s New in Insulin-Related Therapy?
  Clinical Use of Concentrated Insulin Products
  Satish K. Garg, MD
  At the Cutting Edge—The Very Latest in Drugs and Devices
  Linda A. DiMeglio, MD, MPH
  Old Problems, New Solutions—Insulin Management through Innovation
  Lori Berard, RN, CDE

• Global Therapeutic Challenges and Solutions in Diabetes Care
  Innovative Approaches to Diabetes Management in Humanitarian Settings
  Philippa Boulle, MBBS (Hons), MPH, DTM&H
  Improving Access to Insulin in Developing Countries
  David Beran, MSc, PhD
  Diabetes Care in Resource Constrained Settings
  Akihiro Seita, MD
  Diabetes in Sub-Saharan Africa—Innovative Approaches to Care
  Kaushik L. Ramaiya, MD, MMED

• Gene Expression and Genome Regulation in Islets and Kidney
  Epigenomic Signatures in Islet Development
  Amanda M. Ackermann, MD, PhD
  Islet Gene Expression Provides Mechanistic Insight into Type 2 Diabetes
  Martijn van de Bunt, MD, PhD
  High-Throughput Functional Analysis of Candidate Regulatory Variants for Type 2 Diabetes
  Bing Ren, PhD
  Genetic and Epigenetic Drivers of Human Diabetic Kidney Disease
  Katalin Susztak, MD, PhD
• Technical Innovations in Islet Transplantation—Novel Approaches
  Bioengineering the Transplant Site—Application to Clinical Therapy
  James Shapiro, MD, PhD
  Novel Devices for Oxygenation and Beta-Cell Delivery
  Klearchos K. Papas, PhD
  Engineering Novel Encapsulation Platforms for Islets
  Cherie Stabler, PhD
  How Will We Know when Beta Cells Have Been Made? The Need for Robust Physiological Assessments
  James D. Johnson, PhD
  Advancing Immunosuppression—Lessons from Kidney Transplantation
  Flavio Vincenti, MD

• Liver Fat and Metabolic Function—Obesity, Gene, and Gut Interactions
  Impact of Hepatic Triglycerides on Metabolism and Liver Disease in Obesity and Diabetes
  Kenneth Cusi, MD, FACP, FACE
  Liver and Subcutaneous Adipose Tissue Cross Talk
  Alan R. Saltiel, PhD
  Metabolic Impact of Acquired vs. Genetic Fatty Liver
  Hannele Yki-Järvinen, MD, FRCP
  Liver–Gut Cross Talk
  Eamonn Quigley, MD

Oral Presentations

MONDAY, JUNE 12
8:00 a.m.-10:00 a.m.
Symposia
• Healthy Lifestyle Matters for Patients with Diabetes and Kidney Disease
  Finding the Good (and Avoiding the Bad) Food Choices for Patients with Diabetes and Kidney Disease
  Jaime Uribarri, MD
  What We Know (and Don’t Know) about Dietary Supplements, Herbs, and Cultural Healing Traditions for Patients with Diabetes and Kidney Disease
  Valerie A. Luyckx, MB, BCh, MSc
  Physical Activity and Weight Management for Patients with Diabetes and Kidney Disease
  T. Alp Ikizler, MD
  Smoking Cessation and Alcohol Reduction in Patients with Diabetes and Kidney Disease
  Ana C. Ricardo, MD, MPH, MS

• Personalized Nutrition—Nutrigenetics, Nutrigenomics—Relevance to Diabetes
  Nutrigenetics and Nutrigenomics—Overview of the Field and Methods
  V. Saroja Voruganti, PhD
  Personalized Nutrition by Prediction of Glycemic Responses
  Hagit Shapiro, PhD
  Variations in Response to Dietary Fat and Carbohydrate—Genetic Determinants
  José M. Ordovás, PhD
  Impact of Genotype on the Role of Vitamin D in Type 1 and Type 2 Diabetes
  Jill M. Norris, MPH, PhD

• Digital Data—Clinical Liability and Patient Safety
  Tsunami of Digital Data—Impact on Clinical Practices
  Geralyn R. Spollett, MSN, ANP-BC, CDE
  Guidance from the Food and Drug Administration
  Courtney H. Lis, PhD
  What Does the e-Patient Expect?
  Amy L. Tenderich, MA

• Combination Therapy in Type 2 Diabetes—Promise Delivered?
  Pathophysiological Rationale for Combination vs. Step-Wise Treatment Approach
  James R. Gavin III, MD, PhD
  Current Fixed-Dose/Fixed-Ratio Combinations—Overview and Clinical Evidence
  Roopa Mehta, MBBS, MRCP
  Fixed-Dose/Fixed-Ratio Combinations—Limitations and Remaining Gaps
  Luigi F. Meneghini, MD, MBA
  The Future of Combination Therapy in the Treatment of Type 2 Diabetes—Which Classes, Why, and When?
  John B. Buse, MD, PhD

• Cellular Energy Balance as a Basis for Metabolic (Dys)Regulation
  Regulation of Cellular Energy Balance by Redox Circuits
  P. Darrell Neuf, PhD
  Lipin-1-Mediated Regulation of Energy Balance
  Karen Reue, PhD
  Glucose Sensing by Uncoupling the Brain
  Sabrina Diano, PhD
  Exercise, Fitness, and Hepatic Mitochondrial Energetics
  John P. Thyfault, PhD, FACSM, FTOCS

• The Neglected Delta Cell
  Patients with Overactivated GCK Have More SST Cells
  Antonio L. Cuesta-Muñoz, MD, PhD
  The Difference Delta Cells Make in Glucose Control
  Mark O. Huising, PhD
  Unique Aspects of Delta-Cell Structure-Function Revealed by High-Resolution Light and Electron Microscopy
  Rafael Arrojo e Drigo, PhD
  Alpha, Beta, Delta of Islet Function and Coordination
  Patrik Rorsman, FRs, FMEdSci

Oral Presentations
10:15 a.m.-11:45 a.m.

- National Scientific & Health Care Achievement Awards Presentation
- Outstanding Scientific Achievement Award Lecture
  Gregory R. Steinberg, PhD

12:00 p.m.-1:00 p.m.

Professional Interest Group Sessions

- Patient-Centeredness in Diabetes Research—Methodology and Opportunities
  Joe V. Selby, MD, MPH

- Metformin and Glyburide in Pregnancy—You Say Goodbye, and I Say Hello
  Worming Our Way into Understanding the Basic Science of Effects of Metformin and Glyburide on the Fetus
  Mary R. Loeken, PhD
  Pro-Glyburide/Anti-Metformin
  Christina Scifres, MD
  Anti-Glyburide/Pro-Metformin
  Janet A. Rowan, MB, ChB
  Question and Discussion Period

- To Screen or Not to Screen for Diabetes
  Pro
  William H. Herman, MD, MPH
  Con
  Naveed Sattar, MD, PhD

- T-Cell Specificities in Initial Disease and Recurrent Disease after Pancreas or Islet Transplantation
  T-Cell Specificities in Initial Disease and Recurrent Disease after Pancreas or Islet Transplantation
  Todd M. Brusko, PhD
  Bart O. Roep, MD, PhD

General Poster Session/Moderated Poster Discussions

2:15 p.m.-4:15 p.m.

Case Studies

- Case-Based Management of Neuropathies
  Typical Distal Symmetric Polyneuropathy in a Diabetes Patient
  J. Robinson Singleton, MD
  Prediabetes and Neuropathy
  Christopher H. Gibbons, MD
  Gastroparesis
  Rodica Pop-Busui, MD, PhD
  Diabetic Neuropathy Mimics Chronic Inflammatory Demyelinating Polyneuropathy
  Vera Bril, MD, FRCP, BSc
  Question and Discussion Period

Symposia

- Cognitive Functioning and Decision-Making in Diabetes
  Long-Term Impact of a Lifestyle Intervention on Cognitive Outcomes among Individuals with Diabetes—Findings from Look AHEAD
  Mark A. Espeland, PhD
  Cognitive Functioning in Youth with Diabetes—Implications for Improving Diabetes Management
  Cynthia A. Berg, PhD
  The “Right” Device at the “Right” Time—Optimizing Benefit
  Katherine Barnard, PhD, CPsychol, AFbPsS
  AFbPsS
  What Is Shared Decision-Making and How Can It Improve Diabetes Care?
  Kellie M. Rodriguez, MSN, MBA, CDE
  Conclusion and Clinical Implications
  John B. Buse, MD, PhD
  Independent Commentary
  Elizabeth R. Seaquist, MD

- Pairing Nutrition and Exercise in Type 1 Diabetes
  The Role of Nutrition in Managing Blood Glucose During and After Exercise
  Francesca Annan, RD, BSc (Hons), MSc
  Twenty-Four Hour Risk of Hypoglycemia following Exercise—Use of Continuous Glucose Monitoring to Guide Dietary Choice
  Peter Adolfsson, MD, PhD
  Exercise in Youth with Type 1 Diabetes—Dietary Behavioral Perspectives
  Craig E. Taplin, MD
  Exercise and Dietary Management—Implications for Artificial Pancreas Systems
  Steven J. Russell, MD, PhD

- Cardiovascular Safety of Insulin Degludec vs. Insulin Glargine in Patients with Type 2 Diabetes at High Risk of Cardiovascular Events (DEVOTE) Trial Results
  Introduction and Trial Design
  Steven P. Marso, MD
  Cardiovascular Outcomes
  Darren K. McGuire, MD, MHSc
  Glycemic Efficacy and Hypoglycemia
  Bernard Zinman, CM, MD, FRCP, FACP
  Safety
  Richard E. Pratley, MD
  Conclusion and Clinical Implications
  John B. Buse, MD, PhD
  Independent Commentary
  Elizabeth R. Seaquist, MD
Hyperglycemia and Adverse Pregnancy Outcome Follow-Up Study (HAPO FUS)
Introductions and Acknowledgments
Boyd E. Metzger, MD
Hypothesis and Study Design
Denise M. Scholtens, PhD
Primary Study Outcomes in HAPO Offspring
Jill Hamilton, MD
Primary Study Outcomes in HAPO Mothers
Patrick M. Catalano, MD
Future Implications
William L. Lowe, Jr., MD
Question and Discussion Period

Preserving the Beta-Cell Function
Assessing Beta-Cell Function
Jerry P. Palmer, MD
Life Span of the Beta Cell in Type 1 Diabetes
Peter A. Gottlieb, MD
Beta-Cell Dysfunction, De-differentiation, and Death in Type 2 Diabetes
Raghavendra G. Mirmira, MD, PhD
How Do We Protect the Beta Cell in Type 1 Diabetes?
Aaron W. Michels, MD

The Integrated Results of the CANVAS Program
Background to the Design of the Trials
Gregory R. Fulcher, MBBS, MD
Methods for the Trials and the Integrated Analyses
Kenneth W. Mahaffey, BS, MD
Effects on Cardiovascular Outcomes
Bruce Neal, MB, ChB, PhD
Effects on Renal Outcomes
Dick de Zeeuw, MD, PhD
Effects on Safety Outcomes
Vlado Perkovic, MBBS, PhD
Implications for Clinical Practice
David R. Matthews, BM, BCh, DPhil
Independent Commentary
Clifford J. Bailey, PhD, FRCP Edin, FRCPath

Genetic Evidence for Causal Relationships in Diabetes
Genetic Risk Score and Type 1 Diabetes
Daniel J. Perry, PhD
Genetic Links between Metabolic Traits and Diabetes
Benjamin F. Voight, PhD
Causal Relationships between Maternal Obesity Traits and Birth Weight
Robin Beaumont, PhD
Causality and Consequence of Noncoding Variation
Stephen B. Montgomery, PhD

Antidiabetic Actions of Leptin in Insulin-Deficient Animal Models
Leptin Regulates Glucose Homeostasis Independent of Insulin
Qingchun Tong, PhD
The Role of the Hypothalamic–Pituitary–Adrenal Axis in Leptin-Mediated Regulation of Glucose Homeostasis
Rachel J. Perry, PhD
Targeting the Brain to Treat Diabetes—Leptin and FGFs
Jarrad Scarlett, MD, PhD

Oral Presentations
4:30 p.m.-6:30 p.m.
Symposia
Systemic Correlates of Diabetic Retinopathy
Bone Marrow Neuropathy in the Pathogenesis of Diabetic Retinopathy
Gian Paolo Fadini, MD, PhD
What Can the Gut Teach Us about the Eye?
Rachel R. Caspi, PhD
Should We Be Treating the Brain Rather than the Retina?
Gavin Oudit, MD, PhD, FRCP
Novel Models of Diabetic Retinopathy
Ira M. Herman, PhD
Opinion Statement
Ann Marie Schmidt, MD
Question and Discussion Period

Exercise-Induced Mediators of Metabolism and Type 2 Diabetes
IL-6 as a Master Exerkine
Bente K. Pedersen, MD, DMSc
Micromanaging Glucose Metabolism in Skeletal Muscle—Role of microRNAs
Anna Krook, PhD
Myonec tin (CTRP15), a Novel Metabolic Myokine?
Guang William Wong, PhD
Regulation of Exercise Capacity by the Bone-Derived Hormone Osteocalcin
Gerard Karsenty, MD, PhD

Enhancing Diabetes Care in Underserved and Low-Income Populations
Overview of New Approaches to Diabetes Care in Medicaid Populations
Victoria L. Mayer, MD, MS
Applying the Kaiser Permanente Safety-Net Model to Diabetes Care in Federally Qualified Health Centers
R. James Du d l, MD
The Health Home Diabetes Project in Washington State
Alice R. Lind, RN, MPH
Delivery of Diabetes Care in the Underserved Populations of Los Angeles County
Wei-An A. Lee, DO

Novel Risk Factors for Gestational Diabetes Mellitus (GDM)—Even More to Think About
Endocrine Disruptors—New Players in the Pathophysiology of GDM in the Human
Tam arra James-Todd, PhD, MPH
Heavy Metals (Cadmium, Lead, Manganese, and Mercury)
Linda Dodds, PhD
Nutritional and Cardiometabolic Biomarkers—Identification of Novel Risk Factors
Cuilin Zhang, MD, PhD, MPH
Racial-Ethnic Disparities in GDM and Its Sequelae
Monique M. Hedderson, PhD

SAN DIEGO, CA | JUNE 9 - 13, 2017

Speakers and presentation titles are subject to change.
• Type 1 Diabetes Immune Intervention Trials

Type 1 Diabetes TrialNet Oral Insulin Trial
Introduction and Background
Jay S. Skyler, MD, MACP
Results and Conclusions
Desmond Schatz, MD
An Oral Insulin Mechanistic Study
Peter A. Gottlieb, MD
Independent Commentary
David M. Maahs, MD, PhD

Imatinib (Gleevec) in New-Onset Type 1 Diabetes
Background and Results
Stephen E. Gitelman, MD
DIAPREV-IT Trial with GAD-Vaccine
Introduction and Background
Åke Lernmark, PhD
Results and Conclusions
Helena Elding Larsson, MD, PhD
Independent Commentary
Joseph Wolfsdorf, MB, BCh

• Successes with Type 1 Diabetes Complications and Survival

Have Patterns in Morbidity and Mortality Due to Type 1 Diabetes Changed?
Janet K. Snell-Bergeon, PhD, MPH
Is the Development and Progression of Complications in the Patient with Type 1 Diabetes Slowing?
Trevor J. Orchard, MD, MMedSci, FAHA, FACE
Studies of Those with 50 or More Years with Type 1 Diabetes—What Have We Learned?
Hillary A. Keenan, PhD
Clinical Care of Older People with Type 1 Diabetes
Trisha Lynette Dunning, PhD, AM, RN, CDE

• Immunity and Inflammation as Mediators of Insulin Resistance

Tissue Resident Macrophages in Metabolic Disease
Christopher K. Glass, MD, PhD
NLRP3 Inflammasome and Metabolism
Vishwa Deep Dixit, DVM, PhD
Tissue-Specific Roles of ABCA1
John S. Parks, PhD
Genomic Control of Metabolism in Macrophages
László Nagy, MD, PhD

• Novel Metabolites and Mediators of Energy and Metabolic Homeostasis

Novel Plasma Mediators of Energy and Metabolic Homeostasis—Small Molecule Intermediates
William E. Kraus, MD
Novel Intestinal Mediators of Energy and Metabolic Homeostasis—The Endocannabinoid System
Nicholas V. DiPatrizio, PhD
Novel Lipid Mediators of Metabolic Homeostasis and Inflammation—Fatty-Acid Esters of Hydroxy Fatty Acids
Barbara B. Kahn, MD

Pancreas Development Revisited from a Human Perspective
New Capabilities for Researching Human Pancreas Development
Neil Hanley, FRCP, PhD
Modeling Monogenic Diabetes Using Pluripotent Stem Cell-Derived Endocrine Cells
James M. Wells, PhD
Adaptation of Human Islet Architecture during Development
Vipul Periwal, PhD
GLIS3 Regulation of Mouse and Human Pancreas Development
Anton M. Jetten, PhD

Oral Presentations

TUESDAY, JUNE 13
7:30 a.m.-9:30 a.m.

Current Issues

• A Modern Update of Thrifty Genes, Set Points, and Other Models of Obesity Pathogenesis

Thrifty Genotypes in the Pathogenesis of Obesity—Con
Guanlin Wang, PhD
Thrifty Genotypes in the Pathogenesis of Obesity—Pro
Ryan L. Minster, PhD, MSIS
Set Point in the Pathogenesis of Obesity—Con
TBD
Set Point in the Pathogenesis of Obesity—Pro
Steven B. Heymsfield, MD

Symposia

• Hypoglycemic-Associated Autonomic Failure (HAAF) in Diabetes Revisited

The Syndrome of HAAF in Diabetes
Samuel Dagogo-Jack, MD
Pathogenesis of HAAF in Rodents
Owen Chan, PhD
Pathogenesis of Impaired Awareness of Hypoglycemia—Insights from Neuroimaging
Bastiaan E. de Galan, MD, PhD
Challenges of Translating Basic Research into Therapies for HAAF
Elizabeth R. Seaquist, MD

• Cognitive Decline—Recognizing and Adapting Diabetes Care Strategies

The Realities of Aging
Jose A. Luchsinger, MD, MPH
Does Diabetes Cause Cognitive Decline?
Alan M. Jacobson, MD
Clinical Strategies to Simplify Treatment and Reduce Hypoglycemia
Peggy Soule Odegard, BSPharm, PharmD, CDE
Adapting Diabetes Self-Management Efforts to Maximize Success
Deborah A. Hinnen, APN, BC-ADM, CDE, FAAN
• Pediatric Diabetes and Associated Comorbidities
  Eating Disorders and Diabetes—Prevalence, Management, and Intervention
  Patricia Colton, MD, MSc, FRCPC
  High-Risk Behaviors and Type 1 Diabetes
  Kimberly A. Driscoll, PhD
  Mental Health Comorbidities in Type 2 Diabetes—The Not-So Hidden Iceberg
  Diana Naranjo, PhD
  Sleep and Obesity/Type 2 Diabetes
  Tamara S. Hannon, MD

• Technology and Automation for Inpatient Insulin Management
  Advances in Glucose Monitoring in the ICU
  Stanley A. Nasraway, MD, FCCM
  Insulin Management Algorithms for the Inpatient Setting
  Cecilia C. Low Wang, MD
  Automated Glucose Control Systems in the Hospital
  Roma Y. Gianchandani, MD
  Impact and Outcomes from Use of Computerized Insulin-Dosing Algorithms in the ICU—Efficacy, Safety, and Implementation
  Jean-Charles Preiser, MD, PhD

• Prediabetes—Are We Missing Opportunities for Intervention and Risk Reduction?
  Prediabetes—Implications of a Shifting Diagnosis
  Rachel Huxley, MA, DPhil
  Pathobiology of Prediabetes—What Do We Know and How Can Epidemiology Help?
  Steven E. Kahn, MB, ChB
  Prediabetes as an Opportunity for Diabetes Prevention
  Jeremy Sussman, MD, MS
  Does the Diagnosis of Prediabetes Change Patient Behavior?
  Richard W. Grant, MD, MPH

• Mechanistic Role of Metabolic Markers in Insulin Action
  Role of Circulating Metabolites in the Mechanism of Heart Failure
  Chih-Hao Lee, PhD
  Postprandial Gut Microbiota-Driven Choline Metabolism Links Dietary Cues to Obesity and Type 2 Diabetes
  J. Mark Brown, PhD
  Novel Mechanisms that Link Lipogenesis and Gluconeogenesis
  Jae Bum Kim, PhD
  Metabolomics-Derived Insights into Mitochondrial Function
  Charles F. Burant, MD, PhD

9:45 a.m.-11:45 a.m.
Oral Presentations
• ADA Presidents Oral Session
For more information please contact:

Phone:
1-800-DIABETES

E-mail:
conventionoperations@diabetes.org

Website:
scientificsessions.diabetes.org